Prognostic impact of clinical factors for immune checkpoint inhibitor with or without chemotherapy in older patients with non-small cell lung cancer and PD-L1 TPS ≥ 50%

IntroductionThe proportion of older patients diagnosed with advanced-stage non-small cell lung cancer (NSCLC) has been increasing. Immune checkpoint inhibitor (ICI) monotherapy (MONO) and combination therapy of ICI and chemotherapy (COMBO) are standard treatments for patients with NSCLC and programm...

Полное описание

Библиографические подробности

Главные авторы:	Shota Takei, Hayato Kawachi, Tadaaki Yamada, Motohiro Tamiya, Yoshiki Negi, Yasuhiro Goto, Akira Nakao, Shinsuke Shiotsu, Keiko Tanimura, Takayuki Takeda, Asuka Okada, Taishi Harada, Koji Date, Yusuke Chihara, Isao Hasegawa, Nobuyo Tamiya, Yuki Katayama, Naoya Nishioka, Kenji Morimoto, Masahiro Iwasaku, Shinsaku Tokuda, Takashi Kijima, Koichi Takayama
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Frontiers Media S.A. 2024-02-01
Серии:	Frontiers in Immunology
Предметы:	chemoimmunotherapy immunochemotherapy immune checkpoint inhibitor non-small-cell lung cancer PD-L1
Online-ссылка:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1348034/full
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!